COMMUNIQUÉS West-GlobeNewswire

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
30/07/2026
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
30/07/2026
Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007's potential in [...]
PharmAla Issues Q3 Financial Statements and AGM Update
30/07/2026
TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
MMI Receives FDA Approval to Advance to Phase II of Patient Enrollment in Groundbreaking REMIND Microsurgical Study in Alzheimer’s Patients
30/07/2026
FDA-approved supplement advances early feasibility study (EFS) toward full enrollment JACKSONVILLE, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- MMI (Medical Microinstruments, Inc.), a robotics company dedicated to [...]
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
30/07/2026
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company [...]
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
30/07/2026
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities BOCA RATON, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio [...]
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
30/07/2026
Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is [...]
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
30/07/2026
Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026 Launched Expanded Access Program ( [...]
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
30/07/2026
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior [...]
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
30/07/2026
Vancouver, Canada, July 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder [...]
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
30/07/2026
Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies for [...]
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
30/07/2026
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA) FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support [...]
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
30/07/2026
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling More than 70% of patients do not [...]
Glow Peptide Stack Launched by Kylo Peptides for Laboratory Use
30/07/2026
Sheridan, Wyoming , July 30, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides has announced that it has added the GLOW peptide stack to its research catalog. The product supplies three separately sealed, lyophilized vials of the [...]
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
30/07/2026
MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
30/07/2026
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technology KANSAS CITY, Kan., July 30, 2026 (GLOBE NEWSWIRE) -- [...]
Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia
30/07/2026
Partnership with Cure HHT strengthens patient engagement and supports streamlined clinical trial execution Harmony-HHT Phase 1/2 trial activates first clinical site at Massachusetts General Hospital, marking an [...]
NewGen Provides Update on K25.ai Investment and Strengthened Financial Position
30/07/2026
NewGen’s total shares outstanding count expected to reach 5.9 million following recently announced share issuance, bolstering market capitalization NewGen’s agreed 13% stake in K25.ai is now valued at approximately US$ [...]
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
30/07/2026
REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutation following [...]

Pages